These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2516565)

  • 1. Pharmacokinetic study of slow-release preparation of sodium valproate (KW-6066N): multiple dose administration test and the steady-state serum level profiles in epileptic patients.
    Takeda A; Hishida H; Amioka K; Sakamoto Y; Terao S; Ishikawa S; Aoki H
    Jpn J Psychiatry Neurol; 1989 Sep; 43(3):515-6. PubMed ID: 2516565
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serum valproic acid concentrations in monotherapy with 1, 2 and multiple administrations per day].
    Stefan H; Burr W; Fröscher W
    Nervenarzt; 1986 Nov; 57(11):640-8. PubMed ID: 3100971
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and plasma levels of sodium valproate monotherapy in the treatment of epilepsies in children: a further study.
    Shirai H; Miura H; Sunaoshi W
    Jpn J Psychiatry Neurol; 1989 Sep; 43(3):517-8. PubMed ID: 2516566
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of slow-release preparations of sodium valproate.
    Yamatogi Y; Yoshinaga H; Oka E; Ohtahara S; Yamashita S; Furuno K; Gomita Y
    Psychiatry Clin Neurosci; 1995 Dec; 49(5-6):309-10. PubMed ID: 8726120
    [No Abstract]   [Full Text] [Related]  

  • 5. A trial of once-daily administration of KW6066N for patients with benign rolandic and primary generalized epilepsy.
    Kugoh T; Hosokawa K; Kashihara K
    Jpn J Psychiatry Neurol; 1988 Sep; 42(3):580-2. PubMed ID: 3149373
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative EEG effects and plasma concentration of sodium valproate: acute and long-term administration to epileptic patients.
    Sannita WG; Gervasio L; Zagnoni P
    Neuropsychobiology; 1989; 22(4):231-5. PubMed ID: 2518602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose sodium valproate therapy for childhood refractory epilepsy.
    Amano R; Mizukawa M; Ohtsuka Y; Ohtahara S
    Jpn J Psychiatry Neurol; 1990 Jun; 44(2):343-4. PubMed ID: 2124287
    [No Abstract]   [Full Text] [Related]  

  • 8. [The pharmacokinetic optimization of depakin in children with epilepsy].
    Shamansurov ShSh
    Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(6):37-8. PubMed ID: 7740873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between valproate formulation and phenytoin concentrations.
    Suzuki Y; Nagai T; Mano T; Arai H; Kodaka R; Matsuoka T; Itagaki Y; Ono J; Okada S
    Eur J Clin Pharmacol; 1995; 48(1):61-3. PubMed ID: 7621850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid pharmacokinetics in children: III. Very high dosage requirements.
    Kriel RL; Fischer JH; Cloyd JC; Green KH; Fraser GL
    Pediatr Neurol; 1986; 2(4):202-8. PubMed ID: 3150281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A single daily dose with valproic acid. A pharmacodynamic and clinical study].
    Pelzl G; Mamoli B
    Wien Klin Wochenschr; 1992; 104(10):286-9. PubMed ID: 1604872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release valproate in partial epilepsy: comparison between VIPe and Gulf VIPe study findings.
    Deleu D; Mesraoua B; Al Hail H; Dsouza A; Mahmoud HA
    Eur J Neurol; 2008 Aug; 15(8):e74; author reply e75. PubMed ID: 18684301
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum valproate concentrations in epileptic children with favourable responses.
    Ishikawa T; Ogino C; Furuyama M; Kanayama M; Awaya A; Yamaguchi A
    Brain Dev; 1987; 9(3):283-7. PubMed ID: 3116876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of generalized epilepsies with long-term EEG guided single dose administration of sodium valproate].
    Stefan H; Hoffmann F; Fichsel H; Burr W; Bülau P; Fröscher W; Penin H
    Nervenarzt; 1983 Aug; 54(8):430-4. PubMed ID: 6413868
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation.
    Hussein Z; Mukherjee D; Lamm J; Cavanaugh JH; Granneman GR
    J Clin Pharmacol; 1994 Jul; 34(7):754-9. PubMed ID: 7929870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of first-line valproate monotherapy in focal epilepsy.
    Jedrzejczak J; Kuncíková M; Magureanu S;
    Eur J Neurol; 2008 Jan; 15(1):66-72. PubMed ID: 18042239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronopharmacokinetics of valproic acid following constant-rate administration in mice and influence of feeding schedule.
    Song JG; Ohdo S; Ogawa N
    Zhongguo Yao Li Xue Bao; 1995 Mar; 16(2):113-7. PubMed ID: 7597908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
    Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.